Outcome of Board Meeting

July 08, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department, Listing Department, Mumbai 400001, India Mumbai 400051, India Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Outcome of Board Meeting We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: 1. To make an investment upto an amount of Rs. 1400 Crores in Natco Pharma South Africa Proprietary Limited, Wholly Owned Subsidiary of the Company. 2. To acquire 19,618,825 shares at a price of ZAR 92.50 (i.e., (₹5.89) per share, thereby increasing the holding from 35.75% to 49% of shares of the Adcock Ingram Holdings Proprietary Limited based out of South Africa, with a total investment cost of ZAR 1,814,741,312.50 (i.e., ₹1069 crores at the prevailing exchange rate) excluding certain associated transaction cost and other expenses. A copy of Press release is also enclosed for your information. The brief disclosure(s) under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as ANNEXURE-I & Meeting commenced at 10.20 a.m. and concluded at 11.50 a.m. Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl.: as above Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd Natco House Road No.2, Banjara Hills Hyderabad-500 034, India NATCO Pharma Limited gets approval from its Board of Directors for increasing its stake in Adcock Ingram Holdings Proprietary Limited to 49% NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) (“NATCO”) has announced that its Board of Directors has approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited (“Adcock Ingram”) subject to customary closing conditions and statutory compliances. This acquisition valued at ₹ 1,069 crores at the prevailing exchange rate will take NATCO’s shareholding in Adcock Ingram from 35.75% to 49%. Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026. Post transaction, NATCO will be recognising 49% of profit after tax of Adcock Ingram in its books. About NATCO Pharma Limited NATCO Pharma Limited is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of US$ 1.82 billion. Established in 1981, NATCO Pharma is well recognised for its innovation in pharmaceutical R&D and emphasis on developing niche, high potential molecules. The company has a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories. Products are manufactured across 9 state-of-the-art facilities certified and approved by leading global regulatory authorities, including the US FDA, Brazil’s ANVISA, Health Canada, and the World Health Organisation. NATCO Pharma exports its products to more than 50 countries worldwide including USA, Brazil and Canada. About Adcock Ingram Holdings Proprietary Limited Adcock Ingram is a South African pharmaceutical company established in 1890 and ranked 2nd in the private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both the private and public sectors of the market. Its portfolio includes an extensive range of Prescription, Over-the-counter (OTC), Consumer and Hospital products, manufactured in three facilities in South Africa and two in India. Its extensive portfolio of products includes well-known household brands such as Panado, Allergex, Epi-max, Citro-Soda, and Myprodol. Adcock Ingram has a 10% market share of the private market, is the leader in the OTC pharmaceutical market, and is the largest supplier of hospital and critical care products in South Africa. For further information or queries please contact: Rajeev Menon – Manager, Investor Relations Email: r.menon@natcopharma.co.in Tel: 040-23547532 / Ext – 323 Follow us on: X (formerly Twitter): https://twitter.com/pharma_natco LinkedIn: https://www.linkedin.com/company/natcopharma ANNEXURE – I Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sl. No. Particulars Details of Investment a) name of the target entity, details in 1) Name of the target entity brief such as size, turnover etc.; NATCO Pharma South Africa Proprietary Limited (“NPSAPL”) 2) Details in brief such as size, turnover etc. 3) Turnover of last 3 years: b) whether the acquisition would fall Yes, it’s an investment in wholly-owned within related party transaction(s) subsidiary and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”; c) industry to which the entity being Investment Holding and Pharmaceuticals acquired belongs; d) objects and impact of acquisition Objective is to enter new geographies for (including but not limited to, growth and increased profitability disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); e) brief details of any governmental or Applicable provisions under Foreign regulatory approvals required for the Exchange Management Act governed by acquisition; Reserve Bank of India and Regulatory approvals of South Africa, etc. f) indicative time period for completion Before the end of July of 2026 of the acquisition; g) consideration - whether cash Cash consideration consideration or share swap or any other form and details of the same; h) cost of acquisition and/or the price at Upto ₹ 1400 Crores which the shares are acquired; i) percentage of shareholding / control 100% wholly owned subsidiary acquired and / or number of shares acquired; j) brief background about the entity 1) Brief background: NPSAPL is a wholly- acquired in terms of products/line of owned subsidiary of NATCO Pharma business acquired, date of Limited incorporated in South Africa for incorporation, history of last 3 years the purposes of having presence in the turnover, country in which the continent of Africa. acquired entity has presence and any other significant information (in 2) Line of business: Investment Holding & brief); Pharmaceuticals 3) Date of incorporation: 31st July, 2025 4) Turnover of last 3 years: NA 5) Country in which the acquired entity will have presence: South Africa ANNEXURE – II Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sl. No. Particulars Details of Investment a) Name of the target entity, details in Adcock Ingram Holdings Proprietary brief such as size, turnover etc.; Limited (“AIHPL”) Founded in 1890 in South Africa, AIHPL is a pharmaceutical company operating across 4 segments: Prescription, Consumer, OTC and Hospitals. It has a diverse portfolio of products ranging from generic and branded formulations to critical-care hospital products as well as consumer & home-care products. Turnover of last 3 years: Jul-Jun 2025: ZAR 9,760 million Jul-Jun 2024: ZAR 9,643 million Jul-Jun 2023: ZAR 9,132 million b) Whether the acquisition would fall No within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c) Industry to which the entity being Pharmaceuticals acquired belongs d) Objects and impact of acquisition Strategic investment to further increase (including but not limited to, the shareholding to 49% in the entity from disclosure of reasons for acquisition the current stake of 35.75% with an of target entity, if its business is objective of expanding geographic [Showing first 8,000 characters — download PDF for full document]